Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Olaf Müller a Department of Tropical
Hygiene and Public Health, Ruprecht Karls University, 69120 Heidelberg,
INF 324, Germany, b Centre de Recherche en Santé de Nouna, Nouna,
Burkina Faso, c Centre National de Recherche et
de Formation sur le Paludisme, Ouagadougou, Burkina Faso, d Centre Français sur la
Population et le Dévelopement, 75270 Paris, Cedex 06, France
Correspondence to: O Müller olaf.mueller{at}urz.uni-heidelberg.de
| |
Abstract |
|---|
|
|
|---|
Objective:
To study the effects of zinc
supplementation on malaria and other causes of morbidity in young
children living in an area holoendemic for malaria in west Africa.
Design:
Randomised, double blind, placebo controlled efficacy trial.
Setting:
18 villages in rural northwestern Burkina Faso.
Participants:
709 children were enrolled; 685 completed the trial.
Intervention:
Supplementation with zinc (12.5 mg zinc
sulphate) or placebo daily for six days a week for six months.
Main outcome measures:
The primary outcome was the
incidence of symptomatic falciparum malaria. Secondary outcomes were
the severity of malaria episodes, prevalence of malaria parasites, mean
parasite densities, mean packed cell volume, prevalence of other
morbidity, and all cause mortality.
Results:
The mean number of malaria episodes per child (defined as a temperature
37.5°C with
5000 parasites/µl)
was 1.7, 99.7% due to infection with Plasmodium
falciparum. No difference was found between the zinc and placebo
groups in the incidence of falciparum malaria (relative risk 0.98, 95%
confidence interval 0.86 to 1.11), mean temperature, and mean parasite
densities during malaria episodes, nor in malaria parasite rates, mean
parasite densities, and mean packed cell volume during cross sectional surveys. Zinc supplementation was significantly associated with a
reduced prevalence of diarrhoea (0.87, 0.79 to 0.95). All cause mortality was non-significantly lower in children given zinc compared with those given placebo (5 v 12, P=0.1).
Conclusions:
Zinc supplementation has no effect on
morbidity from falciparum malaria in children in rural west Africa, but it does reduce morbidity associated with diarrhoea.
|
What is already known on this topic
What this study adds
|
| |
Introduction |
|---|
|
|
|---|
The annual incidence of malaria is about 300-500 million cases, causing between 1.5 and 2.7 million deaths.1 Tropical Africa accounts for 90% of the morbidity and mortality attributed to malaria; severe disease and death mainly occur among infants in remote rural areas. 2 3 Prevailing poverty, lack of functioning health services, climatic and environmental change, and the rapid spread of chloroquine resistance contribute to a deteriorating malaria situation in Africa.1-6
Zinc deficiency is common in children in developing
countries.7 It has been associated with an increased
susceptibility to a variety of infections because of its effects on the
immune system.8 In several studies, mainly from Asia and
Latin America, zinc supplementation has been shown to have therapeutic
and preventive effects on acute and chronic diarrhoea, dysentery, and
pneumonia.
9 10
Only two studies have provided data on the
possible efficacy of zinc supplementation in reducing morbidity from
malaria.
11 12
We aimed to test the hypothesis that zinc
supplementation reduces morbidity from falciparum malaria in African children.
| |
Participants and methods |
|---|
|
|
|---|
Study area
Our study took place between June and December 1999 in the Nouna
district of northwestern Burkina Faso. Malaria is a major cause of
morbidity and mortality in children in this region.
Study design
Our study was designed as a randomised, placebo controlled, double
blind efficacy trial. Eligible children13 were aged
between 6 and 31 months at enrolment and were permanent residents in 18 of the 39 villages of the study area. We recruited children by lottery.
Children were allocated zinc or placebo in blocks of 30 (15 zinc, 15 placebo) by computer generated randomly permutated codes (prepared by
the World Health Organization). We excluded children with serious
underlying illness, and we excluded from the final analysis those who
were absent from the study area for more than 14 consecutive days.
Assuming a mean of one malaria episode per child per season and
allowing for 20% loss to follow up, we used a sample size of 720 children to detect a 20% reduction in episodes of falciparum malaria
with 90% power (
=0.05).
Laboratory procedures
Blood was usually taken by finger prick and was analysed for the
species specific parasite density per microlitre by counting against
500 white blood cells and multiplying by 16 (assuming 8000 white blood
cells per microlitre of blood). If no parasites were seen in 400 fields
on the thick film a negative result was declared.
Statistical analysis
Analysis was by intention to treat. The primary outcome was
the incidence of clinical episodes of falciparum malaria (in the
presence or absence of Plasmodium malariae or P
ovale). An episode was defined as an axillary temperature of
37.5°C or higher with at least 5000 parasites per microlitre and no
other obvious causes for the fever.14 Secondary outcomes
were the duration and severity of falciparum malaria episodes, the
prevalence of other causes of morbidity, and all cause mortality.
Diarrhoea, fever, and cough were calculated by the number of child days
of the respective disease divided by the total number of days of observation.
|
2 analysis to test differences in distributions and
t tests to compare arithmetic means.
Ethical aspects
We received ethical approval for our study from the ethical
committee of the Heidelberg University Medical School and the Ministry
of Health in Burkina Faso. The trial was explained to the Nouna health
district authorities, the villagers, and the head of each participating
compound. Oral consent was obtained from the parents and carers of the
children before enrolment. Sick children seen during surveys or visits
by the supervisors were treated in the village or referred to Nouna
hospital free of charge.
| |
Results |
|---|
|
|
|---|
Of 713 eligible children, 709 were enrolled and randomised to either zinc (n=356) or placebo (n=353). Overall, 661 of 685 children (96%) were examined during the cross sectional surveys. The two groups were similar in terms of ethnic origin and sex (about 50% girls in both groups) at baseline, except for the children being slightly older in the zinc group (18.7 v 17.5 months, P=0.03). The prevalence of malnutrition was high at baseline (table 1), with 36% of children below -2 z score for height for age (stunting) and 25% below the -2 z score for weight for height (wasting).
Parasitological results were available for 2065 of 2324 (89%) febrile
episodes (table 2). Over the six months of the study, the mean number
of episodes of falciparum malaria a month was 0.38 (parasite density
1/µl), 0.28 (
5.000/µl), and 0.02 (
100 000/µl), with no
differences between the zinc and placebo groups at any of the
respective three parasite thresholds (relative risk 0.99, 95%
confidence interval 0.89 to 1.11, P=0.94; 0.98, 0.86 to 1.11, P=0.77;
1.00, 0.64 to 1.60, P=0.91). Also no difference was found between the
two groups for mean temperature (38.3°C v 38.3°C)
and mean parasite density (44 529 v 44 316) during
episodes of falciparum malaria (
37.5°C with
5000
parasites/µl).
|
No differences were found in the number of days with fever (relative risk 1.01, 0.95 to 1.07, P=0.62) and the number of days with cough (1.05, 0.97 to 1.15, P=0.22) between the two groups, but the number of days with diarrhoea was significantly lower in the zinc group (0.87, 0.79 to 0.95, P=0.002; table 2 ).
More children in the placebo group than zinc group died during the
study (12 v 5), but this difference did not reach
significance. The estimated relative risk in the survival analysis with
a proportional hazards model was 0.41 (0.15 to 1.19, P=0.1). The
relative risk did not change appreciably (0.47) when covariates were
adjusted for.
| |
Discussion |
|---|
|
|
|---|
We found no evidence for zinc supplementation being effective against falciparum malaria in a population of west African children with a high prevalence of malnutrition and zinc deficiency. Our study was a large randomised controlled trial, which had reasonable power to detect a moderate efficacy of the intervention. Case detection was intense and sustained, loss to follow up was small, and individual randomisation made systematic errors unlikely. Dilution of the intervention through fieldworkers mixing up the allocation of zinc or placebo also seems unlikely owing to training and supervision.
Our results do not confirm the findings of two community based studies on zinc supplementation and malaria. 11 12 One study, on children aged 7-28 months in the Gambia, showed 32% fewer clinical episodes of malaria in children given zinc compared with those given placebo after follow up over 15 months.11 This was, however, a small study on 110 children matched for age and sex, zinc supplementation was given only twice weekly, no information was provided on the methods for diagnosis of malaria, and the effects on malaria were only of borderline significance. The other study looked at the effects of zinc supplementation on morbidity from malaria in 274 children aged 6-60 months in Papua New Guinea.12 The children were randomly assigned to 10 mg zinc gluconate or placebo for six days a week for 10 months. The trial reported a 30-35% reduction in attendances to a health centre due to malaria in those children receiving zinc compared with those receiving placebo.
Even mild zinc deficiency can impair multiple mediators of host immunity.8 Some evidence shows that zinc deficiency predominantly affects the cell mediated immune system.15-19 In this context, our inability to show an effect of zinc supplementation on morbidity from malaria may provide evidence for cell mediated immunity being less important in malaria in humans. Furthermore, such a hypothesis would be supported by the overwhelming evidence for malaria not behaving as an opportunistic infection in African children with HIV or AIDS.20-22
Overall, 17 of the 709 (2.4%) children died during the study, which
confirms the unacceptably high level of childhood mortality from
malaria in rural African regions.1-3 We found a tendency for zinc to be protective against all cause mortality, which could be a
real finding given the known effects of zinc on gastrointestinal and
respiratory infections. Our study was not designed to look in detail at
the effects of zinc on other causes of morbidity, and such findings
must be interpreted with caution.
| |
Acknowledgments |
|---|
We thank Walter Fiehn of Heidelberg Medical School for determining the serum zinc values, the team of the Heidelberg Tropical Institute for quality control of the malaria slides, Brian Greenwood for his advice during the design and implementation of the study, the staff of the Centre de Recherche en Santé de Nouna, and the children and their parents.
Contributors: OM was responsible for the overall coordination of the study and contributed to the study design, enrolment and examination of the children, field supervision, and data analysis; he will act as guarantor for the paper. HB was responsible for data analysis and contributed to the study coordination. ABvZ was responsible for the coordination and supervision of the fieldwork and contributed to the analysis and interpretation of the data. YY was responsible for the management of the data in Nouna and contributed to the design of the study. DAD contributed to the design, field supervision, and laboratory supervision of the study. ATK contributed to the coordination, field supervision, and analysis and interpretation of the data. AG and BK contributed to the design and coordination of the study. MG contributed to the study design and coordination and data analysis. All authors contributed to the writing of the paper.
| |
Footnotes |
|---|
Funding: The World Health Organization and the Deutsche Forschungsgemeinschaft (SFB 544, control of tropical infectious diseases).
Competing interests: None declared.
The full version of this article
appears on the BMJ's website
| |
References |
|---|
|
|
|---|
| 1. |
World Health Organization.
World malaria situation in 1994.
Wkly Epidemiol Rec
1997;
72:
269-292 |
| 2. |
Greenwood B, Bradley A, Greenwood A, Byass P, Jammeh K, Marsh K, et al.
Mortality and morbidity from malaria among children in a rural area of the Gambia, West Africa.
Trans R Soc Trop Med Hyg
1987;
81:
478-486 |
| 3. |
Snow RW, Craig M, Deichmann U, Marsh K.
Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population.
Bull WHO
1999;
77:
624-640 |
| 4. |
Kilian A, Langi P, Talisuna A, Kabagambe G.
Rainfall pattern, El Nino and malaria in Uganda.
Trans R Soc Trop Med Hyg
1999;
93:
22-23 |
| 5. |
Marsh K.
Malaria disaster in Africa.
Lancet
1998;
352:
924 |
| 6. |
Müller O, Garenne M.
Childhood mortality in Africa.
Lancet
1999;
353:
673 |
| 7. |
Gibson RS, Ferguson EL.
Assessment of dietary zinc in a population.
Am J Clin Nutr
1998;
68:
S430-S434 |
| 8. |
Shankar AH, Prasad AS.
Zinc and immune function: the biological basis of altered resistance to infection.
Am J Clin Nutr
1998;
68:
S447-S463 |
| 9. |
Umeta M, West CE, Haidar J, Deurenberg P, Hautvast JGAJ.
Zinc supplementation and stunted infants in Ethiopia: a randomised controlled trial.
Lancet
2000;
355:
2021-2026 |
| 10. |
Bhurta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, et al of the Zinc Investigators' Collaborative Group.
Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials.
J Pediatr
1999;
135:
689-697 |
| 11. |
Bates CJ, Evans PH, Dardenne M, Prentice A, Lunn PG, Northrop-Clewes CA, et al.
A trial of zinc supplementation in young rural Gambian children.
Br J Nutr
1993;
69:
243-255 |
| 12. |
Shankar AH, Genton B, Tamja S, Arnold S, Wu L, Baisor M, et al.
Zinc supplementation can reduce malaria-related morbidity in preschool children [abstract].
Am J Trop Med Hyg
1997;
57:
249 |
| 13. |
Benzler J, Sauerborn R.
Rapid risk household screening by neonatal arm circumference: results from a cohort study in rural Burkina Faso.
Trop Med Int Health
1999;
3:
962-974 |
| 14. |
D'Alessandro U, Olaleye BO, McGuire W, Langerock P, Bennett S, Aikins MK, et al.
Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme.
Lancet
1995;
345:
479-483 |
| 15. |
Pekareh RS, Sandstead HH, Jacob RA, Barcome DF.
Abnormal cellular immune responses during acquired zinc deficiency.
Am J Clin Nutr
1979;
32:
1466-1471 |
| 16. |
Chandra RK, Au B.
Single nutritient deficiency and cell-mediated immune responses, I. Zinc.
Am J Clin Nutr
1980;
33:
736-738 |
| 17. |
Beisel WR.
Single nutritients and immunity.
Am J Clin Nutr
1982;
35:
S417-S468 |
| 18. |
Chandra RK.
1990 McCollum award lecture. Nutrition and immunity: lessons from the past and new insights into the future.
Am J Clin Nutr
1991;
53:
1087-1101 |
| 19. |
Beck FWJ, Prasad AS, Kaplan J, Fitzgerald JT, Brewer GJ.
Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans.
Am J Physiol
1997;
272:
E1002-E1007 |
| 20. |
Müller O, Moser R.
The clinical and parasitological presentation of falciparum malaria in Uganda is unaffected by HIV infection.
Trans R Soc Trop Med Hyg
1990;
84:
336-338 |
| 21. |
Butcher GA.
HIV and malaria: a lesson in immunology?
Parasitol Today
1992;
8:
307-311 |
| 22. |
Chandramohan D, Greenwood BM.
Is there an interaction between human immunodeficiency virus and Plasmodium falciparum?
Int J Epidemiol
1998;
27:
296-301 |
(Accepted 22 March 2001)